Text Size
9842 studies found for:    NCI

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
21 Active, not recruiting Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: obatoclax mesylate;   Other: laboratory biomarker analysis;   Genetic: gene expression analysis;   Genetic: microarray analysis;   Drug: bortezomib
22 Recruiting Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Conditions: Childhood Low-grade Cerebellar Astrocytoma;   Childhood Low-grade Cerebral Astrocytoma;   Childhood Mixed Glioma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Oligodendroglioma;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma;   Recurrent Childhood Visual Pathway Glioma
Interventions: Drug: selumetinib;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Other: pharmacogenomic studies
23 Active, not recruiting Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Recurrent Adult Brain Tumor
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Procedure: therapeutic conventional surgery;   Other: pharmacological study;   Other: laboratory biomarker analysis
24 Recruiting Fulvestrant With or Without Bortezomib in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   Stage III Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: fulvestrant;   Drug: bortezomib;   Other: laboratory biomarker analysis
25 Active, not recruiting Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia
Conditions: Adult Acute Basophilic Leukemia;   Adult Acute Eosinophilic Leukemia;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Blastic Phase Chronic Myelogenous Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: entinostat;   Drug: sorafenib tosylate;   Other: pharmacological study;   Other: laboratory biomarker analysis
26 Recruiting Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Adenocarcinoma of the Stomach;   Recurrent Esophageal Cancer;   Recurrent Gastric Cancer
Intervention: Drug: Akt inhibitor MK2206
27 Recruiting Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
Conditions: Childhood Mixed Glioma;   Untreated Childhood Anaplastic Astrocytoma;   Untreated Childhood Brain Stem Glioma;   Untreated Childhood Giant Cell Glioblastoma;   Untreated Childhood Glioblastoma;   Untreated Childhood Gliosarcoma
Interventions: Drug: veliparib;   Drug: temozolomide;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Other: pharmacological study;   Other: laboratory biomarker analysis
28 Recruiting Tivantinib in Treating Patients With Previously Treated Metastatic or Recurrent Malignant Mesothelioma
Conditions: Epithelial Mesothelioma;   Recurrent Malignant Mesothelioma;   Sarcomatous Mesothelioma;   Stage II Malignant Mesothelioma;   Stage III Malignant Mesothelioma;   Stage IV Malignant Mesothelioma
Interventions: Drug: tivantinib;   Other: laboratory biomarker analysis
29 Completed Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma
Conditions: Brain and Central Nervous System Tumors;   Lymphoma;   Neuroblastoma;   Retinoblastoma;   Sarcoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Drug: becatecarin
30 Completed FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-Small Cell Lung Cancer
Conditions: Extensive Stage Small Cell Lung Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer;   Recurrent Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Recurrent Non-Small Cell Lung Cancer
Intervention: Drug: FR901228
31 Completed Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: T-cell Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: prednisone;   Drug: vincristine sulfate;   Drug: daunorubicin hydrochloride;   Drug: asparaginase;   Drug: methotrexate;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: mercaptopurine;   Drug: leucovorin calcium;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: thioguanine;   Radiation: radiation therapy;   Drug: nelarabine;   Drug: pegaspargase;   Other: pharmacological study;   Other: laboratory biomarker analysis
32 Completed Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor
Condition: Gastrointestinal Stromal Tumor
Interventions: Drug: imatinib mesylate;   Procedure: conventional surgery
33 Completed Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: vorinostat;   Other: laboratory biomarker analysis
34 Completed Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: ixabepilone;   Other: laboratory biomarker analysis
35 Completed Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
Conditions: Adult Angiosarcoma;   Adult Epithelioid Sarcoma;   Adult Leiomyosarcoma;   Adult Malignant Fibrous Histiocytoma;   Adult Neurofibrosarcoma;   Adult Synovial Sarcoma;   Ovarian Sarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Uterine Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage III Uterine Sarcoma;   Stage IV Adult Soft Tissue Sarcoma;   Stage IV Uterine Sarcoma;   Uterine Carcinosarcoma;   Uterine Leiomyosarcoma
Intervention: Drug: sorafenib tosylate
36 Completed
Has Results 		O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: O6-benzylguanine;   Drug: temozolomide
37 Completed Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: tandutinib;   Other: laboratory biomarker analysis
38 Active, not recruiting Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
Conditions: B-cell Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia
Interventions: Drug: alvespimycin hydrochloride;   Genetic: DNA analysis;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: pharmacological study
39 Recruiting Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma
Interventions: Drug: selumetinib;   Drug: temozolomide;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
40 Recruiting Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Advanced Lymphoma, Multiple Myeloma, or Solid Tumors
Conditions: AIDS-related Diffuse Large Cell Lymphoma;   AIDS-related Diffuse Mixed Cell Lymphoma;   AIDS-related Diffuse Small Cleaved Cell Lymphoma;   AIDS-related Immunoblastic Large Cell Lymphoma;   AIDS-related Lymphoblastic Lymphoma;   AIDS-related Peripheral/Systemic Lymphoma;   AIDS-related Small Noncleaved Cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   HIV-associated Hodgkin Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Grade I Lymphomatoid Granulomatosis;   Recurrent Grade II Lymphomatoid Granulomatosis;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Multiple Myeloma;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: bendamustine hydrochloride;   Drug: veliparib;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study;   Biological: rituximab
To Top

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
† Indicates status has not been verified in more than two years